Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.

Autor: Tun AM; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, Kansas, USA., Patel RD; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., St-Pierre F; Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Ouchveridze E; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, Kansas, USA., Niu A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Thordardottir T; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Obasi J; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Rosenthal A; Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, USA., Pophali PA; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Fenske TS; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Karmali R; Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Johnston PB; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Sep; Vol. 99 (9), pp. 1712-1720. Date of Electronic Publication: 2024 Jun 04.

Real-world CAR-T findings for large B-cell lymphoma from a single institution experience.

Autor: Lutfi F; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Tun AM; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Hoffmann M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA.

Publikováno v: Annals of palliative medicine [Ann Palliat Med] 2024 May; Vol. 13 (3), pp. 729-732. Date of Electronic Publication: 2024 Apr 18.

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.

Autor: Tun AM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Westwood, KS, USA., Wang Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Matin A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Micallef I; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Johnston PB; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Porrata L; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Paludo J; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Bisneto JV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rosenthal A; Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA., Tun HW; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA., Cerhan JR; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Publikováno v: HemaSphere [Hemasphere] 2023 Apr 04; Vol. 7 (4), pp. e869. Date of Electronic Publication: 2023 Apr 04 (Print Publication: 2023).

Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Autor: Tun AM; Division of Hematology, Mayo Clinic, Rochester, Minnesota; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Kansas City, Kansas. Electronic address: atun@kumc.edu., Maliske S; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, Iowa., Wang Y; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Micallef I; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Porrata L; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Paludo J; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Bisneto JV; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Rosenthal A; Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, Florida., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Farooq U; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, Iowa., Johnston PB; Division of Hematology, Mayo Clinic, Rochester, Minnesota. Electronic address: johnston.patrick@mayo.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2022 Sep; Vol. 28 (9), pp. 610-617. Date of Electronic Publication: 2022 Jun 22.

Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.

Autor: Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: bennani.nora@mayo.edu., Tun AM; Division of Hematology, Mayo Clinic, Rochester, MN; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS., Carson KR; Research Service, St Louis Veterans Affairs Medical Center, St Louis, MO; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Geiger JL; Division of Hematology, Mayo Clinic, Rochester, MN., Maeda LS; Division of Oncology, Stanford Cancer Institute, Stanford, CA., Savage KJ; Department of Medical Oncology, Centre for Lymphoid Cancer, Vancouver, BC, Canada., Rose J; Department of Medical Oncology, Centre for Lymphoid Cancer, Vancouver, BC, Canada., Pinter-Brown L; Divisions of Hematology/Oncology, UCLA, Los Angeles, CA., Lunning MA; Divisions of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE., Abramson JS; Divisions of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA., Bartlett NL; Division of Oncology, Washington University School of Medicine, St. Louis, MO., Vose JM; Divisions of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE., Evens AM; U Mass Memorial Cancer Center, Worcester, MA., Smith SM; Divisions of Hematology/Oncology, University of Chicago, Chicago, IL., Horwitz SM; Division of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN., Advani RH; Division of Oncology, Stanford Cancer Institute, Stanford, CA.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Apr; Vol. 22 (4), pp. e250-e260. Date of Electronic Publication: 2021 Oct 16.